Background: BCR-ABL1 negative chronic myeloproliferative neoplasms (CMPNs) are a heterogeneous group of clonal hematological malignancies. Some genetic aberrations have been described to cause these diseases, most of them activating tyrosine kinase (TK) genes. However, in last years, different groups have described mutations in other molecules involved in the same signalling pathways that could have important roles in the disease.

One of them is the CBL (Casitas B-lineage Lymphoma) family of E3-Ubiquitin-ligase proteins that are encoded by three genes: C-CBL, CBL-B and CBL-C. CBLS are involved in the negative regulation of several tyrosine-kinases, as EGFR, FGFR or SYK. Several groups have demonstrated that mutations in the RING Finger domain of C-CBL result in loss of ubiquitination and degradation of TKs (1-14). This effect contributes to deregulation of downstream targets of the signalling pathways in which they are involved. Most mutations found in this gene have been detected in AML patients, and some authors have been proposed C-CBL and JAK2 mutations as exclusive events (12,14).

Methods: We have used dhPLC to detect sequence mutations on samples from 382 BCR-ABL1 negative CMPN patients, 145 of them negative and 237 positive for the V617F/JAK2 mutation (see Figure 1). They were no 11qUPD selected. We included 20 samples from healthy individuals as controls. Firstly we analyzed the entire coding sequence of C-CBL, CBL-B and CBL-C in 44 of the V617F/JAK2 negative patients and in the control samples. For the remaining patients we only studied the exons coding for the RING Finger domain, as well as C-CBL exon 12 (Proline-rich region).

Results: We have found five non-described mutations in C-CBL, three of them located in the RING Finger domain (T402H, C416W, P417R), and two in the Proline-Rich region (S675C and A678V). T402H, P417R and S675C were found in V617F/JAK2 positive patients (S675C in two patients). In addition we could detect a non-described mutation (R462W) in the RING Finger domain of CBL-B in a V617F/JAK2 positive polycythemia vera patient. However, our experimental design does not allow to know if both mutations are present in the same clone or in different ones.

![Figure 1](image1.png)

**Figure 1.** dhPLC elution profiles of C-CBL exons 9 (up) and 12 (down). Sequencing analysis showed that samples with an abnormal elution profile had C416W and A678V mutations, respectively.

![Figure 2](image2.png)

**Figure 2.** Structure of C-CBL and position of the mutations described in the literature. The changes detected in our study are marked in red. Three of them were located in the RING Finger domain (T402H and P417R in an ET patient and a PMF patient both V617F/JAK2 positive, respectively, and C416W in an atypical CMPN V617F/JAK2 negative patient) and two in the Proline Rich region, (S675C in two V617F/JAK2 positive patients one with an ET and the other with PV).

Conclusions:
1) We have found that C-CBL is mutated in the 1.4% (5/382) of the CMPN patients unselected for chromosome 11qUPD
2) Mutations detected were located in the RING Finger domain, but also in the Proline-rich region of C-CBL in 3 of the 382 CMPNs patients. One of the Proline-rich region mutations (S675C) was detected in two cases (a PV and an ET).
3) Our results suggest that mutations in CBL genes and JAK2 are not exclusive events: 1.7% (4/237) of V617F/JAK2 positive patients showed mutations in C-CBL and 1 of them in CBL-B

References:

1. Sargin et al. 2007
2. Caligari et al. 2007
3. Abbas et al. 2008
4. Slappe et al. 2008
5. Dunbar et al. 2008
13. Matamatsu et al. 2010
14. Jäger et al. 2010

This work has been funded with the help of the Spanish Ministry of Science and Innovation (SAF 2007-62473), the PIUNA Program of the University of Navarra and the Caja Navarra Foundation through the Program “You choose, you decide” (Project 10.830). PA and IE have predoctoral grants from the Department of Education of the Government of Navarra